US Patent 12,427,207 Patent Estate Scope, Claim Coverage, and US Landscape for 18F Silicon-Fluoride “Radiohybrid” Compositions with Citrate Buffer
US Patent 12,427,207 is a formulation-and-agent specific claim set for “radiohybrid” pharmaceutical compositions built around a silicon-fluoride (Si-F) motif and a chelating group, with strict physicochemical constraints (pH 4.0 to 6.0) and a bounded citrate buffer load (0.1 to 200 mM, including specific narrower windows). Claim 7 narrows the radioisotope to 18F while converting M3+ to non-radioactive metal, and Claim 8 narrows that metal to Ga. The estate risk profile in the US is driven by (i) how broadly the “radiohybrid agent” is defined by generic structural language and salts/isomers, (ii) whether competitors can design around citrate concentration and pH targets, and (iii) whether downstream products are controlled by additional related method-of-use, chelator, linker, and radiochemistry process patents not contained in this single grant.
What is US Patent 12,427,207 “radiohybrid” claim scope and what does it cover in the US?
Answer: The patent covers pharmaceutical compositions that combine (a) a radiohybrid agent containing a silicon-fluoride group plus a chelating group, (b) either the Si-fluoride fluorine is 18F or the chelating group contains a chelated radioactive metal, (c) a pH range of 4.0 to 6.0, and (d) a citrate buffer present from 0.1 to 200 mM. Dependent claims narrow citrate range, set-point citrate concentration (1.1 mM ±10%), set pH windowing, add ethanol in a selected range (Claim 6), and specify a non-radioactive metal (Ga) when fluorine is 18F (Claims 7-8).
Claim 1: Core scope (agent + buffer + pH + radio/metal boundary)
Claim 1 elements (all required):
- Composition: “A pharmaceutical composition comprising a radiohybrid agent containing a silicon-fluoride group and a chelating group.”
- Radio/metal option (logical “either/or”):
- “either the fluorine of the silicon-fluoride group is 18F”
- or “the chelating group contains a chelated radioactive metal.”
- Radiohybrid agent definition:
- The radiohybrid agent is (per your excerpt) in a form “wherein the radiohybrid agent is:” followed by placeholder text indicating “an isomer or salt thereof.”
- The excerpt also defines M3+ as “a chelated radioactive or non-radioactive metal.”
- Physicochemical constraints:
- pH of 4.0–6.0
- “further comprises 0.1–200 mM citrate buffer.”
Interpretation for design-arounds (US litigation-relevant):
- The claim ties coverage to composition-level parameters (pH and citrate concentration). That creates clear potential for pH/buffer substitutions, provided competitors can keep their composition outside the recited ranges while still meeting stability and formulation needs.
- The claim also ties coverage to the structural presence of a silicon-fluoride group and a chelating group in the same “radiohybrid agent.” Competitors can seek to avoid literal coverage by using a different radiochemistry motif (no Si-F), or no chelator combination, or separate components (non-radiohybrid delivery) depending on construction of the “radiohybrid agent” term.
Claim 2 and Claim 3: Specific citrate buffers (range and target)
- Claim 2: citrate buffer 1–15 mM
- Claim 3: citrate buffer 1.1 mM (±10%)
- That is effectively 0.99–1.21 mM.
Design-around relevance: Even if pH remains in-range, moving citrate concentration to below 1 mM or above 15 mM can potentially avoid Claims 2-3 while still potentially falling under Claim 1 if still within 0.1–200 mM.
Claim 4 and Claim 5: pH narrowing
- Claim 4: pH 4.5–5.5
- Claim 5: pH 5.0
Design-around relevance: If competitors can formulate at pH 4.0–4.5 or 5.5–6.0, they may avoid dependent claims 4-5 while remaining within Claim 1. If they shift outside Claim 1’s pH envelope, they attempt full design-out.
Claim 6: Ethanol with a specific pH claim dependency
- Claim 6: “The pharmaceutical composition of claim 5 comprising 5–50 mg/mL ethanol.”
Because Claim 6 depends on Claim 5, it requires:
- pH = 5.0, and
- ethanol concentration 5–50 mg/mL.
Design-around relevance: ethanol inclusion is frequently used for radiopharmaceutical stability/solubility. If competitors retain the citrate and pH but adjust ethanol outside 5–50 mg/mL, they may avoid Claim 6.
Claim 7: 18F on Si-F, non-radioactive M3+ on the chelator
- Claim 7: “fluorine is 18F and M3+ is a chelated non-radioactive metal.”
Impact: This narrows the radioisotope logic. It does not require the chelated metal to be radioactive, so a competitor using 18F-labeled Si-F chemistry while chelating a stable metal could still land in this claim scope if they meet pH and citrate constraints.
Claim 8: Ga-only narrowing
- Claim 8: Claim 7 where the metal is Ga.
Impact: Ga chelation is common in Ga radiopharmaceuticals. This dependent claim makes Ga-specific infringement plausible for any 18F Si-F “radiohybrid” formulation that uses gallium as the chelated metal, with citrate and pH in range.
How broad is the “radiohybrid agent” definition and what claim terms are most likely to drive infringement?
Answer: The broadest infringement hinge is whether the accused product contains (1) a silicon-fluoride group and (2) a chelating group in the same “radiohybrid agent,” plus (3) a pH 4.0–6.0 and citrate buffer 0.1–200 mM. Dependent claims then lock narrower operational parameters (pH 4.5–5.5 or 5.0, citrate 1–15 mM or 1.1 mM, ethanol 5–50 mg/mL, and Ga as M3+ when fluorine is 18F).
Potential breadth signals from the provided claims excerpt
- “silicon-fluoride group” is a specific functional motif but can support a range of substitution patterns if the claim language is broad to structural variants.
- “radiohybrid agent” is likely to be defined in the specification by a general structural formula (not included in your prompt excerpt). The phrase “isomer or salt thereof” suggests coverage extends to stereoisomers and salt forms without changing the underlying functional architecture.
- “M3+ is a chelated radioactive or non-radioactive metal” indicates that the chelator can bind either radioactive or stable trivalent metals, expanding the scope beyond pure radiometal scenarios.
- The “either” logic in Claim 1 means the claim does not require both (i) 18F at Si-F and (ii) a radioactive metal chelated. The accused composition only needs one of those features, plus the silicon-fluoride+chelator agent architecture and the formulation parameters.
Most litigation-relevant factual inquiries (what claim interpretation will focus on)
- Whether the accused product’s radionuclide exists as 18F bound to a silicon-fluoride group (literal vs. equivalence arguments depend on claim construction).
- Whether any radiometal present is “chelated” by the same chelating group in the radiohybrid agent.
- Whether measured pH and citrate concentration fall inside the numeric windows (these are objective lab parameters).
- Whether ethanol is present at 5–50 mg/mL if pH is 5.0.
When does US Patent 12,427,207 lose exclusivity and what is the practical exclusivity timeline?
Answer: Exclusivity depends on the patent’s expiration (not derivable from the claim text alone). Without the filing and priority dates (or USPTO maintenance/term), the exact US patent expiration cannot be computed from the information provided.
What Orange Book status or FDA regulatory tie exists for US 12,427,207?
Answer: Orange Book listing status is not determinable from the claims excerpt alone. Patent-to-product mapping requires the patent’s bibliographic identifiers, listed drugs, and the FDA labeling hooks tied to the listed active ingredient(s).
Which formulations are explicitly protected by US 12,427,207 (pH, citrate, ethanol) and how do they segment by claim?
Answer: The patent is formulation-parameter segmented. Claim 1 establishes the outer formulation perimeter, while Claims 2-6 carve inside it for narrower buffers, specific pH targets, and ethanol inclusion.
Protected parameter matrix (from provided claims)
| Claim |
pH requirement |
Citrate buffer requirement |
Ethanol requirement |
Radio/metal specifics |
| 1 |
4.0–6.0 |
0.1–200 mM |
Not required |
Si-F fluorine is 18F OR chelated radioactive M3+; M3+ can be radioactive or non-radioactive |
| 2 |
Same as Claim 1 |
1–15 mM |
Not required |
Same as Claim 1 |
| 3 |
Same as Claim 2 |
1.1 mM (±10%) |
Not required |
Same as Claim 2 |
| 4 |
4.5–5.5 |
Same as Claim 1 |
Not required |
Same as Claim 1 |
| 5 |
5.0 |
Same as Claim 1 |
Not required |
Same as Claim 1 |
| 6 |
5.0 |
Same as Claim 5 |
5–50 mg/mL ethanol |
Same as Claim 5 |
| 7 |
Same as Claim 1 |
Same as Claim 1 |
Not required |
fluorine is 18F AND M3+ is non-radioactive |
| 8 |
Same as Claim 7 |
Same as Claim 1 |
Not required |
M3+ = Ga (when fluorine is 18F) |
What generic entry risks exist for US 12,427,207 and how could a challenger design around?
Answer: The risk of direct literal infringement is highest for any US product that uses a silicon-fluoride containing radiohybrid agent with a chelator, while formulating at pH 4.0–6.0 with citrate between 0.1–200 mM. Dependent-claim exposure is highest if the citrate is 1–15 mM or ~1.1 mM, pH is 5.0 or 4.5–5.5, ethanol is in 5–50 mg/mL, and Ga is used as the chelated non-radioactive M3+ with 18F present on Si-F.
Likely design-around levers (most actionable)
- Move pH outside 4.0–6.0 (strongest reduction of Claim 1 exposure). This also likely avoids dependent pH-limited claims 4-6.
- Move citrate buffer outside 0.1–200 mM (strongest reduction).
- If staying within Claim 1 pH, adjust citrate to:
- below 1 mM or above 15 mM to reduce Claims 2-3 exposure, and/or
- away from 1.1 mM (±10%) to avoid Claim 3.
- If pH is fixed at 5.0, adjust ethanol outside 5–50 mg/mL to avoid Claim 6.
- Avoid Ga as M3+ in the 18F Si-F setting to avoid Claim 8, while still potentially meeting Claim 1 or 7.
Claim-construction pressure points for challengers
- “silicon-fluoride group” is a chemistry anchor. Any redesign that changes the radiolabeling handle (for example, using a different silicon functionality) can target the structural limitation.
- The “radiohybrid agent containing … silicon-fluoride group and a chelating group” can be attacked if the accused product’s architecture is not a single agent meeting both functional requirements.
What patent litigation affects US 12,427,207 (PTAB, district court, settlements)?
Answer: Litigation and PTAB history cannot be determined from the claim text alone. A complete landscape requires the patent number’s prosecution record and docket-level mapping, which is not included in the provided information.
Key Takeaways
- US 12,427,207 is a composition-scope patent built on a silicon-fluoride “radiohybrid agent” plus chelation, combined with tight formulation parameters: pH 4.0–6.0 and citrate buffer 0.1–200 mM.
- Dependent claims materially narrow exposure to citrate 1–15 mM and specifically 1.1 mM (±10%), pH 4.5–5.5 and especially pH 5.0, and ethanol 5–50 mg/mL.
- Radio/metal dependency is structured for infringement risk: Claim 7 covers 18F on Si-F with a non-radioactive M3+ chelated; Claim 8 further targets Ga as M3+ under those conditions.
- Primary design-around risk reduction is formulation perimeter control (pH and citrate) and chelated metal selection (avoid Ga in the 18F context), with architecture redesign (avoid the Si-F radiohybrid structure) as the strongest chemistry-level lever.
FAQs
-
Does US 12,427,207 require both 18F and a radioactive chelated metal?
Claim 1 is written with an “either” structure: coverage exists with 18F on the silicon-fluoride group OR with a chelated radioactive metal in the chelating group, plus the agent architecture and formulation parameters.
-
What citrate concentrations avoid the narrower dependent claims?
Claims 2-3 target 1–15 mM and 1.1 mM (±10%). Shifting citrate outside those ranges while staying within Claim 1’s 0.1–200 mM window can reduce exposure to dependent claims.
-
If a product is at pH 5.0, is ethanol automatically implicated?
No. Ethanol inclusion is only required by Claim 6, which depends on pH 5.0 and requires 5–50 mg/mL ethanol.
-
How specific is Ga in the claims?
Ga is only explicitly required in Claim 8, which depends on Claim 7 (18F on Si-F and non-radioactive M3+). If Ga is not used, Claim 8 is avoided, while other claims may still be relevant.
-
What is the strongest single design-around lever?
Moving the formulation outside pH 4.0–6.0 or outside citrate 0.1–200 mM targets the claim 1 perimeter, reducing the baseline infringement risk.
References
- US Patent 12,427,207 (claims provided in prompt).
